Question

Give one example on antibody drug conjugate (ADC) which was approved by the US FDA and used in the treatment of Hodgkin’s lymphoma and systemic anaplastic large-cell lymphoma?

Answer 1

One example on antibody drug conjugate (ADC) which was approved by the US FDA and used in the treatment of Hodgkin’s lymphoma and systemic anaplastic large-cell lymphoma is Brentuximab vedotin.It comes with Trade name: Adcetris. It was approved On March 20, 2018 by the Food and Drug Administration.

It is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an "­­­­­­­­­antineoplastic agent and a monoclonal antibody".

Brentuximab Vedotin Is Used For:

• Treatment of adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
• Treatment of patients with Classical Hodgkins Lymphoma (cHL) at high risk of relapse or progression as post autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
• Treatment of patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for auto-HSCT.
• Treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.
• Treatment of patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF).

Brentuximab Vedotin Is Given As:

• An infusion into a vein (intravenous, IV) over 30 minutes.
• The amount of drug give also depends upon weight, your general health or other health problems, and the type of cancer or condition patient has.

Brentuximab Vedotin Side Effects:

• Low blood counts.
• Peripheral neuropathy (numbness and tingling of the hands and feet)
• Fatigue (feeling tired or weak)
• Nausea
• Diarrhea
• Fever
• Rash
• Upper respiratory infection
• Lung problems (if previously treated with bleomycin)